Applied Filters
Tough year ahead as generics take bite out of market: Teva
Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.
Pharma group asks USTR to drop India from watch list
The lobby group for India’s pharma industry has asked the US Trade Representative office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.
Chinese national jailed for stealing medical devices tech
A US district court has sentenced a Chinese national to 27 months in federal prison for the theft of trade secrets from two American medical device manufacturers.
Thailand suspends medical marijuana patents
Thailand’s government has suspended all patents for medical marijuana products, a little more than a month after the country’s parliament voted to approve marijuana for medical use and research.
Indian committee advocates compulsory licensing and price caps
Indian pharmaceutical companies should be encouraged to grant compulsory licences and prices of some patented medicines should be capped, an Indian government panel has said.
Gilead announces licence and collaboration deal with Yuhan
Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.
Indian Supreme Court reinstates Monsanto GM cotton seed patent
The Supreme Court of India has ruled that biotechnology company Monsanto’s patent for genetically modified cotton seeds is valid and enforceable in the country.
United Therapeutics signs 3D bioprinting technology deal
Maryland-based United Therapeutics has inked a licence, development and commercialisation agreement with CollPlant, an Israeli biotech company, for 3D bioprinted lung transplants.
Novartis signs deal to bring CAR T therapy to China
Novartis has teamed up with a clinical-stage biopharmaceutical firm in efforts to bring the Swiss company’s proprietary cancer treatment to patients in China.
Bombay court finds company liable for infringing Glenmark TM
The Bombay High Court has imposed Rs 1.5 crore of costs on a pharmaceutical company which infringed India-based Glenmark Pharmaceuticals’ trademarks.
